The metabolism of Paroxetine can be decreased when combined with Cholecalciferol. Paroxetine may increase the QTc-prolonging activities of Paliperidone. The risk or severity of adverse effects can be increased when Thiopental is combined with Paroxetine. The metabolism of Etoricoxib can be decreased when combined with Paroxetine. Paroxetine may increase the QTc-prolonging activities of Ofloxacin. Paroxetine may increase the QTc-prolonging activities of Quinidine. The metabolism of Mirabegron can be decreased when combined with Paroxetine. The risk or severity of adverse effects can be increased when Pregabalin is combined with Paroxetine. The risk or severity of adverse effects can be increased when Paroxetine is combined with Doxepin. The metabolism of Phenacetin can be decreased when combined with Paroxetine. The metabolism of Carteolol can be decreased when combined with Paroxetine. The risk or severity of adverse effects can be increased when Paroxetine is combined with Trimipramine. Paroxetine may increase the hypoglycemic activities of Acarbose. The serum concentration of Tizanidine can be increased when it is combined with Paroxetine. The risk or severity of adverse effects can be increased when Gabapentin is combined with Paroxetine. Paroxetine may increase the antiplatelet activities of Parecoxib. The metabolism of Nitrofural can be decreased when combined with Paroxetine. Paroxetine may increase the antiplatelet activities of Valdecoxib. The metabolism of Temazepam can be decreased when combined with Paroxetine. The metabolism of Dopamine can be decreased when combined with Paroxetine. Paroxetine may increase the hypoglycemic activities of Insulin Aspart. The serum concentration of Doxorubicin can be increased when it is combined with Paroxetine. The metabolism of Propranolol can be decreased when combined with Paroxetine. Safrazine may increase the serotonergic activities of Paroxetine. The risk or severity of adverse effects can be increased when Dantrolene is combined with Paroxetine. The risk or severity of adverse effects can be increased when Paraldehyde is combined with Paroxetine. The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Paroxetine. The risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Paroxetine. The risk or severity of adverse effects can be increased when Methocarbamol is combined with Paroxetine. The risk or severity of adverse effects can be increased when Paroxetine is combined with Protriptyline. The metabolism of Pindolol can be decreased when combined with Paroxetine. The metabolism of Methylphenidate can be decreased when combined with Paroxetine. The risk or severity of adverse effects can be increased when Metyrosine is combined with Paroxetine. Nalbuphine may increase the serotonergic activities of Paroxetine. The metabolism of Progesterone can be decreased when combined with Paroxetine. The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Paroxetine. Paroxetine may increase the hyponatremic activities of Trichlormethiazide. Paroxetine may increase the serotonergic activities of Zimelidine. The serum concentration of Celiprolol can be increased when it is combined with Paroxetine. The metabolism of Formoterol can be decreased when combined with Paroxetine. The risk or severity of adverse effects can be increased when Tiagabine is combined with Paroxetine. The risk or severity of adverse effects can be increased when Cetirizine is combined with Paroxetine. Paroxetine may increase the QTc-prolonging activities of Erythromycin. The metabolism of Zolpidem can be decreased when combined with Paroxetine. The metabolism of Perospirone can be decreased when combined with Paroxetine. The risk or severity of adverse effects can be increased when Flibanserin is combined with Paroxetine. The metabolism of Carbamazepine can be decreased when combined with Paroxetine. The metabolism of Irinotecan can be decreased when combined with Paroxetine. The risk or severity of adverse effects can be increased when Ramelteon is combined with Paroxetine. The metabolism of Doxorubicin can be decreased when combined with Paroxetine. The metabolism of Benzyl alcohol can be decreased when combined with Paroxetine. The metabolism of Trabectedin can be decreased when combined with Paroxetine. The serum concentration of Tamoxifen can be increased when it is combined with Paroxetine. The risk or severity of adverse effects can be increased when Brimonidine is combined with Paroxetine. The metabolism of Efavirenz can be decreased when combined with Paroxetine. The metabolism of Cephalexin can be decreased when combined with Paroxetine. The risk or severity of adverse effects can be increased when Paroxetine is combined with Procarbazine. The risk or severity of adverse effects can be increased when Hydroxyzine is combined with Paroxetine. Paroxetine may increase the hyponatremic activities of Methyclothiazide. The metabolism of Tolterodine can be decreased when combined with Paroxetine. The risk or severity of adverse effects can be increased when Desloratadine is combined with Paroxetine. Etoperidone may increase the serotonergic activities of Paroxetine. Paroxetine may increase the hypoglycemic activities of Chlorpropamide. The metabolism of Levodopa can be decreased when combined with Paroxetine. The risk or severity of adverse effects can be increased when Desflurane is combined with Paroxetine. Paroxetine may increase the anticoagulant activities of Fluindione. Paroxetine may increase the QTc-prolonging activities of Toremifene. The metabolism of Paroxetine can be decreased when combined with Midostaurin. The metabolism of Ropivacaine can be decreased when combined with Paroxetine. The risk or severity of adverse effects can be increased when Ethotoin is combined with Paroxetine. The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Paroxetine. Paroxetine may increase the QTc-prolonging activities of Perflutren. The risk or severity of adverse effects can be increased when Paroxetine is combined with Amisulpride. Etorphine may increase the serotonergic activities of Paroxetine. Buspirone may increase the serotonergic activities of Paroxetine. The risk or severity of adverse effects can be increased when Paroxetine is combined with Prothipendyl. The metabolism of Paroxetine can be decreased when combined with Manidipine. Linezolid may increase the serotonergic activities of Paroxetine. The risk or severity of adverse effects can be increased when Paroxetine is combined with Ecopipam. The metabolism of Methotrimeprazine can be decreased when combined with Paroxetine. The serum concentration of the active metabolites of Fosaprepitant can be reduced when Fosaprepitant is used in combination with Paroxetine resulting in a loss in efficacy. The metabolism of Amsacrine can be decreased when combined with Paroxetine. The metabolism of Haloperidol can be decreased when combined with Paroxetine. The risk or severity of adverse effects can be increased when Etidocaine is combined with Paroxetine. The metabolism of Brompheniramine can be decreased when combined with Paroxetine. The metabolism of 4-Methoxyamphetamine can be decreased when combined with Paroxetine. The metabolism of Testosterone can be decreased when combined with Paroxetine. The metabolism of Caffeine can be decreased when combined with Paroxetine. The metabolism of Mianserin can be decreased when combined with Paroxetine. The metabolism of Amphetamine can be decreased when combined with Paroxetine. Paroxetine may increase the QTc-prolonging activities of Ceritinib. The metabolism of Nicardipine can be decreased when combined with Paroxetine. The risk or severity of adverse effects can be increased when Sumatriptan is combined with Paroxetine. Paroxetine may increase the hypoglycemic activities of Glyburide. The metabolism of Paroxetine can be decreased when combined with Cinacalcet. Paroxetine may increase the hypoglycemic activities of Tolazamide. Paroxetine may increase the hypoglycemic activities of Miglitol. The risk or severity of adverse effects can be increased when Paroxetine is combined with Lurasidone. The risk or severity of adverse effects can be increased when Procaine is combined with Paroxetine. The therapeutic efficacy of Iobenguane can be decreased when used in combination with Paroxetine. The metabolism of Promethazine can be decreased when combined with Paroxetine. The metabolism of Terfenadine can be decreased when combined with Paroxetine. Paroxetine may increase the hypoglycemic activities of Insulin Lispro. The serum concentration of Afatinib can be increased when it is combined with Paroxetine. The serum concentration of Oxprenolol can be increased when it is combined with Paroxetine. The risk or severity of adverse effects can be increased when Chlormezanone is combined with Paroxetine. The risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Paroxetine. The serum concentration of Pimozide can be increased when it is combined with Paroxetine. The risk or severity of adverse effects can be increased when Adipiplon is combined with Paroxetine. The metabolism of Darifenacin can be decreased when combined with Paroxetine. The serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Paroxetine resulting in a loss in efficacy. The risk or severity of adverse effects can be increased when Loprazolam is combined with Paroxetine. The metabolism of Cinnarizine can be decreased when combined with Paroxetine. The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Paroxetine. The risk or severity of adverse effects can be increased when Triprolidine is combined with Paroxetine. The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Paroxetine. The metabolism of Arformoterol can be decreased when combined with Paroxetine. Paroxetine may increase the QTc-prolonging activities of Azithromycin. The metabolism of Valproic Acid can be decreased when combined with Paroxetine. The risk or severity of adverse effects can be increased when Paroxetine is combined with Desmopressin. Indalpine may increase the serotonergic activities of Paroxetine. Benmoxin may increase the serotonergic activities of Paroxetine. The metabolism of Donepezil can be decreased when combined with Paroxetine. Paroxetine may increase the QTc-prolonging activities of Ziprasidone. The risk or severity of adverse effects can be increased when Canertinib is combined with Paroxetine. The risk or severity of adverse effects can be increased when Norflurane is combined with Paroxetine. Paroxetine may increase the anticoagulant activities of Warfarin. The risk or severity of adverse effects can be increased when Deramciclane is combined with Paroxetine. The risk or severity of adverse effects can be increased when Doxylamine is combined with Paroxetine. Paroxetine may increase the hyponatremic activities of Bendroflumethiazide.